Janus Henderson Group
NTLA icon

Janus Henderson Group’s Intellia Therapeutics NTLA Stock Holding History

Janus Henderson Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$615K Hold
47,957
– – ﹤0.01% 1916
2025
Q4 		$431K Hold
47,957
– – ﹤0.01% 2070
2025
Q3 		$827K Hold
47,957
– – ﹤0.01% 1757
2025
Q2 		$449K Hold
47,957
– – ﹤0.01% 2001
2025
Q1 		$387K Hold
47,957
– – ﹤0.01% 2090
2024
Q4 		$560K Hold
47,957
– – ﹤0.01% 1981
2024
Q3 		$985K Buy
47,957
+10,575
+28% +$244K ﹤0.01% 1676
2024
Q2 		$837K Sell
37,382
-459
-1% -$10.9K ﹤0.01% 1715
2024
Q1 		$1.04M Buy
37,841
+6
+0% +$167 ﹤0.01% 1623
2023
Q4 		$1.15M Sell
37,835
-38
-0.1% -$1.09K ﹤0.01% 1547
2023
Q3 		$1.2M Buy
37,873
+2
+0% +$78 ﹤0.01% 1465
2023
Q2 		$1.54M Buy
37,871
+6,572
+21% +$267K ﹤0.01% 1377
2023
Q1 		$1.17M Sell
31,299
-22,846
-42% -$896K ﹤0.01% 1543
2022
Q4 		$1.89M Buy
54,145
+41,714
+336% +$1.98M ﹤0.01% 1114
2022
Q3 		$696K Sell
12,431
-6
-0% -$372 ﹤0.01% 1448
2022
Q2 		$644K Buy
12,437
+17
+0.1% +$863 ﹤0.01% 1596
2022
Q1 		$902K Sell
12,420
-258,581
-95% -$21.9M ﹤0.01% 1561
2021
Q4 		$32M Sell
271,001
-6,826
-2% -$855K 0.01% 677
2021
Q3 		$37.3M Buy
277,827
+24,730
+10% +$3.74M 0.02% 634
2021
Q2 		$41M Buy
253,097
+217,437
+610% +$16.9M 0.02% 623
2021
Q1 		$2.86M Buy
+35,660
New +$2.39M ﹤0.01% 1123

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Janus Henderson Group's NTLA Position: Q1 2026 in Review

Janus Henderson Group held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 47,957 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

Janus Henderson Group first reported a position in NTLA in Q1 2021 and has held it in 21 quarters since. The position peaked at $41M in Q2 2021. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Janus Henderson Group held 47,957 shares of Intellia Therapeutics worth $615K as of Q1 2026.
  • Janus Henderson Group left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1916 holding.
  • Janus Henderson Group first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Janus Henderson Group's Intellia Therapeutics position peaked at $41M in Q2 2021.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.